Louis DN, Ohgaki H, Wiestler OD, Cavenee WK: WHO classification of tumours of the central nervous system, 4th ed, 2016.

Brandes A.A. Tosoni A. Cavallo G. Reni M. Franceschi E. Bonaldi L. Bertorelle R. Gardiman M. Ghimenton C. Iuzzolino P. Pession A. Blatt V. Ermani M. Gicno

Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study.

J Clin Oncol. 24: 4746-4753Kouwenhoven M.C. Kros J.M. French P.J. Biemond-ter Stege E.M. Graveland W.J. Taphoorn M.J. Brandes A.A. van den Bent M.J.

1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment.

Eur J Cancer. 42: 2499-2503van den Bent M.J. Brandes A.A. Taphoorn M.J. Kros J.M. Kouwenhoven M.C. Delattre J.Y. Bernsen H.J. Frenay M. Tijssen C.C. Grisold W. Sipos L. Enting R.H. French P.J. Dinjens W.N. Vecht C.J. Allgeier A. Lacombe D. Gorlia T. Hoang-Xuan K.

Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.

J Clin Oncol. 31: 344-350Louis D.N. Perry A. Reifenberger G. von Deimling A. Figarella-Branger D. Cavenee W.K. Ohgaki H. Wiestler O.D. Kleihues P. Ellison D.W.

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Acta Neuropathol. 131: 803-820Franceschi E. Mura A. De Biase D. Tallini G. Pession A. Foschini M.P. Danieli D. Pizzolitto S. Zunarelli E. Lanza G. Bartolini D. Silini E.M. Visani M. Di Oto E. Tosoni A. Minichillo S. Lamberti G. Lanese A. Paccapelo A. Bartolini S. Brandes A.A.

The role of clinical and molecular factors in low-grade gliomas: what is their impact on survival?.

Future Oncol. 14: 1559-1567Smith J.S. Perry A. Borell T.J. Lee H.K. O'Fallon J. Hosek S.M. Kimmel D. Yates A. Burger P.C. Scheithauer B.W. Jenkins R.B.

Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.

J Clin Oncol. 18: 636-645Clark K.H. Villano J.L. Nikiforova M.N. Hamilton R.L. Horbinski C.

1p/19q testing has no significance in the workup of glioblastomas.

Neuropathol Appl Neurobiol. 39: 706-717Vogazianou A.P. Chan R. Backlund L.M. Pearson D.M. Liu L. Langford C.F. Gregory S.G. Collins V.P. Ichimura K.

Distinct patterns of 1p and 19q alterations identify subtypes of human gliomas that have different prognoses.

Neuro Oncol. 12: 664-678Pinkham M.B. Telford N. Whitfield G.A. Colaco R.J. O'Neill F. McBain C.A.

FISHing Tips: What Every Clinician Should Know About 1p19q Analysis in Gliomas Using Fluorescence in situ Hybridisation.

Clin Oncol (R Coll Radiol). 27: 445-453Woehrer A. Sander P. Haberler C. Kern S. Maier H. Preusser M. Hartmann C. Kros J.M. Hainfellner J.A.

Research Committee of the European Confederation of Neuropathological S: FISH-based detection of 1p 19q codeletion in oligodendroglial tumors: procedures and protocols for neuropathological practice - a publication under the auspices of the Research Committee of the European Confederation of Neuropathological Societies (Euro-CNS).

Clin Neuropathol. 30: 47-55

1p/19q co-deleted fibrillary astrocytomas: Not everything that is co-deleted is an oligodendroglioma.

Ann Diagn Pathol. 46: 151519

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Ellison DW, Figarella-Branger D, Perry A, Reifenberger G, von Deimling A: WHO CLASSIFICATION OF TUMOURS OF THE CENTRAL NERVOUS SYSTEM. Lyon: IARC, 2016.

de Biase D. Acquaviva G. Visani M. Sanza V. Argento C.M. De Leo A. Maloberti T. Pession A. Tallini G.

Molecular Diagnostic of Solid Tumor Using a Next Generation Sequencing Custom-Designed Multi-Gene Panel.

Diagnostics (Basel). 10Visani M. Acquaviva G. Marucci G. Paccapelo A. Mura A. Franceschi E. Grifoni D. Pession A. Tallini G. Brandes A.A. de Biase D.

Non-canonical IDH1 and IDH2 mutations: a clonal and relevant event in an Italian cohort of gliomas classified according to the 2016 World Health Organization (WHO) criteria.

J Neurooncol. 135: 245-254Horbinski C. Nikiforova M.N. Hobbs J. Bortoluzzi S. Cieply K. Dacic S. Hamilton R.L.

The importance of 10q status in an outcomes-based comparison between 1p/19q fluorescence in situ hybridization and polymerase chain reaction-based microsatellite loss of heterozygosity analysis of oligodendrogliomas.

J Neuropathol Exp Neurol. 71: 73-82Sim J. Nam D.H. Kim Y. Lee I.H. Choi J.W. Sa J.K. Suh Y.L.

Comparison of 1p and 19q status of glioblastoma by whole exome sequencing, array-comparative genomic hybridization, and fluorescence in situ hybridization.

Med Oncol. 35: 60Scheie D. Andresen P.A. Cvancarova M. Bo A.S. Helseth E. Skullerud K. Beiske K.

Fluorescence in situ hybridization (FISH) on touch preparations: a reliable method for detecting loss of heterozygosity at 1p and 19q in oligodendroglial tumors.

Am J Surg Pathol. 30: 828-837Ball M.K. Kollmeyer T.M. Praska C.E. McKenna M.L. Giannini C. Raghunathan A. Jentoft M.E. Lachance D.H. Kipp B.R. Jenkins R.B. Ida C.M.

Frequency of false-positive FISH 1p/19q codeletion in adult diffuse astrocytic gliomas.

Neurooncol Adv. 2: vdaa109Woehrer A. Hainfellner J.A.

Molecular diagnostics: techniques and recommendations for 1p/19q assessment.

CNS Oncol. 4: 295-306Natte R. van Eijk R. Eilers P. Cleton-Jansen A.M. Oosting J. Kouwenhove M. Kros J.M. van Duinen S.

Multiplex ligation-dependent probe amplification for the detection of 1p and 19q chromosomal loss in oligodendroglial tumors.

Brain Pathol. 15: 192-197Jha P. Sarkar C. Pathak P. Sharma M.C. Kale S.S. Gupta D. Chosdol K. Suri V.

Detection of allelic status of 1p and 19q by microsatellite-based PCR versus FISH: limitations and advantages in application to patient management.

Diagn Mol Pathol. 20: 40-47Dubbink H.J. Atmodimedjo P.N. van Marion R. Krol N.M.G. Riegman P.H.J. Kros J.M. van den Bent M.J. Dinjens W.N.M.

Diagnostic Detection of Allelic Losses and Imbalances by Next-Generation Sequencing: 1p/19q Co-Deletion Analysis of Gliomas.

J Mol Diagn. 18: 775-786Lass U. Hartmann C. Capper D. Herold-Mende C. von Deimling A. Meiboom M. Mueller W.

Chromogenic in situ hybridization is a reliable alternative to fluorescence in situ hybridization for diagnostic testing of 1p and 19q loss in paraffin-embedded gliomas.

Brain Pathol. 23: 311-318Zepeda-Mendoza C.J. Vaubel R.A. Zarei S. Ida C.M. Matthews M. Acree S. Raghunathan A. Giannini C. Jenkins R.B.

Concomitant 1p/19q co-deletion and IDH1/2, ATRX, and TP53 mutations within a single clone of "dual-genotype" IDH-mutant infiltrating gliomas.

Acta Neuropathol. 139: 1105-1107Kallioniemi O.P. Kallioniemi A. Piper J. Isola J. Waldman F.M. Gray J.W. Pinkel D.

Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors.

Genes Chromosomes Cancer. 10: 231-243Cowell J.K. Barnett G.H. Nowak N.J.

Characterization of the 1p/19q chromosomal loss in oligodendrogliomas using comparative genomic hybridization arrays (CGHa).

J Neuropathol Exp Neurol. 63: 151-158Liu X.Y. Gerges N. Korshunov A. Sabha N. Khuong-Quang D.A. Fontebasso A.M. Fleming A. Hadjadj D. Schwartzentruber J. Majewski J. Dong Z. Siegel P. Albrecht S. Croul S. Jones D.T. Kool M. Tonjes M. Reifenberger G. Faury D. Zadeh G. Pfister S. Jabado N.

Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations.

Acta Neuropathol. 124: 615-625Reuss D.E. Sahm F. Schrimpf D. Wiestler B. Capper D. Koelsche C. Schweizer L. Korshunov A. Jones D.T. Hovestadt V. Mittelbronn M. Schittenhelm J. Herold-Mende C. Unterberg A. Platten M. Weller M. Wick W. Pfister S.M. von Deimling A.

ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.

Acta Neuropathol. 129: 133-146